Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Treat cold granules versus Banlangen granules for common cold with acute exacerbation of COPD
ChiCTR2300070253Phase 4Recruiting
- Sponsor
- Henan Provincial People's Hospital
- Start
- Oct 2020
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of ban lan gen in nasopharyngitis and chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by Henan Provincial People's Hospital. Primary endpoints: Antipyretic first onset of action time, Time to return to normal body temperature and 6 more. Started Oct 2020; status: recruiting.
02
Drugs
ban lan gen
03
Conditions
nasopharyngitischronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on ChiCTR2300070253.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300070253.